Shin Nippon Biomedical Laboratories, Ltd. (JP:2395) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Shin Nippon Biomedical Laboratories (SNBL) has announced a collaboration with Astellas Pharma to enhance the drug discovery ecosystem in Tsukuba City by providing non-clinical study support at the SakuLab™-Tsukuba innovation center. SNBL, Japan’s largest nonclinical CRO, will offer its expertise in drug discovery to support startups, academia, and pharmaceutical companies at Tsukuba, one of Japan’s leading life science centers. This partnership aims to accelerate the development of new drugs and advanced technologies within the Tsukuba ecosystem.
For further insights into JP:2395 stock, check out TipRanks’ Stock Analysis page.